{"transactions":[{"id":3241134,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-08T11:41:12.000Z","date":"2026-09-04","kind":"grant","planned":false,"acquired":true,"shares":2503050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":2503050,"derivative":{"exercise_price":3.89,"expiration_date":"2036-09-04","underlying":"Common Stock","underlying_shares":2503050},"source":{"system":"sec-edgar","filing":"0001193125-26-384391","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526384391/ownership.xml","form_type":"4"}},{"id":686447,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:06:09.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":250956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board."}],"balance_after":941087,"derivative":{"exercise_price":1.49,"exercise_date":"2026-08-12","expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":250956},"source":{"system":"sec-edgar","filing":"0001193125-26-352206","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000119312526352206/ownership.xml","form_type":"4"}},{"id":917274,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-06T01:37:38.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":690131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in 12 equal monthly installments, commencing on the grant date and subject to the reporting person's continued service as Interim Chief Executive Officer through the applicable vesting date."}],"balance_after":690131,"derivative":{"exercise_price":1.49,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":690131},"source":{"system":"sec-edgar","filing":"0001193125-26-039951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000119312526039951/ownership.xml","form_type":"4"}},{"id":929034,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-01-29T01:30:09.000Z","date":"2026-01-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the \"Arrangement Agreement\"), by and between the Issuer and XenoTherapeutics, Inc. (the \"Parent\"), Xeno Acquisition Corp. (the \"Purchaser\"), and XOMA Royalty Corporation (\"XRC\"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right (\"CVR\") per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001723092-26-000002","document":"form4-01282026_080105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000172309226000002/form4-01282026_080105.xml","form_type":"4"}},{"id":1182422,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T12:57:37.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000095017025048894/ownership.xml","form_type":"4"}},{"id":1473299,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T20:35:07.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":27200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":27200,"derivative":{"exercise_price":3.8,"expiration_date":"2034-06-16","underlying":"Common Shares","underlying_shares":27200},"source":{"system":"sec-edgar","filing":"0001415889-24-017654","document":"form4-06202024_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924017654/form4-06202024_040603.xml","form_type":"4"}},{"id":1558183,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T20:32:03.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":44024,"price":3.83,"value":168611.92,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":44024,"derivative":{"exercise_price":3.83,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":44024},"source":{"system":"sec-edgar","filing":"0000950170-24-038098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000095017024038098/ownership.xml","form_type":"4"}},{"id":1858934,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:22:07.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":27200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":27200,"derivative":{"exercise_price":11.66,"expiration_date":"2033-06-07","underlying":"Common Shares","underlying_shares":27200},"source":{"system":"sec-edgar","filing":"0001209191-23-036298","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919123036298/doc4.xml","form_type":"4"}},{"id":1936470,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T20:41:02.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":139355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":206186,"source":{"system":"sec-edgar","filing":"0001209191-23-021404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000120919123021404/doc4.xml","form_type":"4"}},{"id":2270465,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T23:30:06.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":49000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":49000,"derivative":{"exercise_price":9.55,"expiration_date":"2032-05-13","underlying":"Common Shares","underlying_shares":49000},"source":{"system":"sec-edgar","filing":"0001209191-22-029370","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919122029370/doc4.xml","form_type":"4"}},{"id":2307051,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-04T20:15:52.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":66831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":66831,"source":{"system":"sec-edgar","filing":"0001140361-22-012919","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000114036122012919/form4.xml","form_type":"4"}},{"id":2502150,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-19T18:21:19.000Z","date":"2021-11-18","kind":"purchase","acquired":true,"shares":15700,"price":12.74,"value":200018.0,"ownership":{"direct":false,"nature":"By Civik Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.47 to $13.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Civik Family Trust, a revocable trust for which the Reporting Person and his spouse are the grantors."}],"balance_after":15700,"source":{"system":"sec-edgar","filing":"0000899243-21-045363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000089924321045363/doc4.xml","form_type":"4"}},{"id":2505028,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-18T22:00:49.000Z","date":"2021-11-16","kind":"purchase","acquired":true,"shares":7500,"price":28.08,"value":210600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.50\nto $28.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-21-065517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121065517/doc4.xml","form_type":"4"}},{"id":2544104,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2021-10-12T23:47:58.000Z","date":"2021-10-07","kind":"grant","acquired":true,"shares":42191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":42191,"derivative":{"exercise_price":16,"expiration_date":"2031-10-07","underlying":"Common Stock","underlying_shares":42191},"source":{"system":"sec-edgar","filing":"0001140361-21-034427","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000114036121034427/form4.xml","form_type":"4"}},{"id":2574872,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-09T21:06:37.000Z","date":"2021-09-07","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3rd) of the shares subject to the option shall vest on September 7, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":42000,"derivative":{"exercise_price":33.89,"expiration_date":"2031-09-07","underlying":"Common Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-21-055321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121055321/doc4.xml","form_type":"4"}},{"id":2745421,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:21:50.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":480000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":2.72,"underlying":"Common Stock","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001209191-21-027390","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027390/doc4.xml","form_type":"4"}},{"id":2745420,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-19T19:21:50.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":68971,"price":38,"value":2620898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share (\"Common Stock\"), was converted into the right to receive $38.00 per share (the \"Offer Price\") in cash, without interest, minus any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-027390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027390/doc4.xml","form_type":"4"}},{"id":2750549,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-13T13:05:30.000Z","date":"2021-04-09","kind":"tax_withholding","acquired":false,"shares":11088,"price":37.94,"value":420678.72,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,859 shares acquired on November 15, 2020 and 1,200 shares acquired on April 1, 2021, in each case, pursuant to Five Prime Therapeutics, Inc.'s 2013 Employee Stock Purchase Plan."}],"balance_after":68971,"source":{"system":"sec-edgar","filing":"0001209191-21-026419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121026419/doc4.xml","form_type":"4"}},{"id":3177298,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-14T16:38:06.000Z","date":"2020-04-13","kind":"grant","acquired":true,"shares":480000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option will vest with respect to one-fourth (1/4) of the shares subject to this option on April 13, 2021 and with respect to one forty-eighth (1/48) of the shares subject to this option monthly thereafter, provided the reporting person provides services to the Company through each such date."}],"balance_after":480000,"derivative":{"exercise_price":2.72,"expiration_date":"2030-04-12","underlying":"Common Stock","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001209191-20-024363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120024363/doc4.xml","form_type":"4"}},{"id":3177297,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-14T16:38:06.000Z","date":"2020-04-13","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of April 13, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the \"Company\") through each such date."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001209191-20-024363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120024363/doc4.xml","form_type":"4"}},{"id":3854984,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-08-02T16:03:41.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":33421,"price":137,"value":4578677.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-044917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044917/doc4.xml","form_type":"4"}},{"id":4112022,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-03T16:07:05.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":33421,"price":68.2,"value":2279312.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest (i) with respect to 25% of the units, on January 1, 2019, and (ii) with respect to 75% of the units, in 12 equal installments every three months with the first installment vesting on April 1, 2019."}],"balance_after":33421,"source":{"system":"sec-edgar","filing":"0001209191-18-000779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118000779/doc4.xml","form_type":"4"}}]}